Have you been diagnosed with B-cell post-transplant lymphoproliferative disorder (PTLD) after an organ transplant? Have you not yet received any type of treatment for this condition? Then you may be eligible for a study to look at the safety and effectiveness of tafasitamab and rituximab combination treatment for PTLD.

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment.

Do you have a new diagnosis of Acute Myeloid Leukemia and are looking for another treatment option? In this study, we are looking to see if the study drug (Tagraxofusp) can help control Leukemia or achieve remission.

The purpose of this study is to find out if we can improve the chance of your leukemia going away (remission) and lower the chance of your leukemia coming back (relapsing) by combining two drugs for acute lymphoblastic leukemia. In this study you will be given the first study drug (Inotuzumab Ozogamicin) for up to 7 weeks and then a second leukemia drug (Blinatumomab) for up to 31 weeks.

Have you been recently diagnosed with follicular lymphoma (a type of non-Hodgkin lymphoma)? You may be able to take part in a research study to learn more about the safety and tolerability of an experimental drug called odronextamab.

Have you been diagnosed with unfavorable risk prostate cancer? Are you looking for treatment options? If so, you may be able to participate in a clinical trial examining different treatment options for prostate cancer.

Phase II/III research study to determine how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer.

Do you have stage 1, HER2-positive breast cancer? Has your surgery already been completed? If so, you may be able to take part in a study to help us learn more about a combination of medications to treat your cancer.

To evaluate the safety and efficacy of BLU-222 therapy in patients with advanced solid tumors.

Do you have metastatic or recurrent lung cancer? Have you already been treated with chemotherapy or immunotherapy? If so, you may qualify for the LungMap protocol, which will help us identify clinical trials you may be eligible for.